ClostraBio is a preclinical-stage pharmaceutical company creating new medicines to treat diseases resulting from intestinal barrier dysfunction, especially those caused by shifts to the microbiome. ClostraBio's first indications are in the treatment and prevention of food allergy, initially peanut allergy, and ClostraBio recently began a program in colitis. ClostraBio has licensed a proprietary drug delivery platform, developed by the ClostraBio co-founders, from the University of Chicago and are using this platform for oral delivery of small molecules and metabolites derived from the microbiome to the GI tract. ClostraBio's founding scientific team are key opinion leaders and world's experts in food allergy, the microbiome, immunology and immuno-engineering, drug delivery, and polymer chemistry. ClostraBio is seeking a Chief Executive Officer and Chief Medical Officer.
Fungal infections can be painful and deadly, and immunocompromised patients (e.g., HIV/AIDS, cancer) have high infection risk. There are no safe and specific treatments to prevent infections in these high-risk patients and infection is largely due to 'good' microbes turning 'bad'. AVnovum is developing novel peptides for preventing fungal infections in these immunocompromised patients. AVnovum is actively seeking development partners and seed funding to pursue pre-clinical testing and IND-enabling studies.
Currently there are several solutions under consideration for disinfecting N95 respirators for re-use, with UV-C as the preferred solution because of ease of deployment and widespread applicability. Problematically, present UV-C disinfection solutions are limited by shadowing, which prevents exposure of the masks to the required effective dose of UV irradiation. The inventors utilized UV-C light field modeling and extensive test measurements to develop a proprietary arrangement of lamps for disinfecting. The configuration eliminates shadowing, allowing for full irradiation and disinfecting of the contaminated N95 respirator surface in the shortest amount of time.
Relying on developers to do web app maintenance is expensive and time-consuming. Many content management system (CMS) operators like Wordpress claim you can 'do it yourself' visually, but after 20-50 plugins, visual interfaces fall short as many dependencies fail. Tharzen offers a visual editing interface for any live website under any CMS, even hard-coded and dynamic web apps.
Parallel Works is a web-based platform that simplifies and automates the complex workflow of parallel computing. They speed up simulation and analytics campaigns across industries by making parallel computers from hybrid clouds and clusters easier to use. Their platform is built on the Parsl and Swift parallel scripting technologies developed over the last decade by Argonne National Laboratory, and is designed to run simulation and analytics on the world's largest computing resources.